Halozyme Therapeutics Inc
NASDAQ:HALO
Intrinsic Value
Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development and commercialization of human enzymes and drug candidates. [ Read More ]
The intrinsic value of one HALO stock under the Base Case scenario is 54.76 USD. Compared to the current market price of 38.64 USD, Halozyme Therapeutics Inc is Undervalued by 29%.
Valuation Backtest
Halozyme Therapeutics Inc
Run backtest to discover the historical profit from buying and selling HALO stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Halozyme Therapeutics Inc
Current Assets | 746.4m |
Cash & Short-Term Investments | 336m |
Receivables | 234.2m |
Other Current Assets | 176.2m |
Non-Current Assets | 986.8m |
PP&E | 74.9m |
Intangibles | 889.7m |
Other Non-Current Assets | 22.2m |
Current Liabilities | 112.5m |
Accounts Payable | 11.8m |
Accrued Liabilities | 100.7m |
Non-Current Liabilities | 1.5B |
Long-Term Debt | 1.5B |
Other Non-Current Liabilities | 37.7m |
Earnings Waterfall
Halozyme Therapeutics Inc
Revenue
|
829.3m
USD
|
Cost of Revenue
|
-192.4m
USD
|
Gross Profit
|
636.9m
USD
|
Operating Expenses
|
-296.8m
USD
|
Operating Income
|
340.1m
USD
|
Other Expenses
|
-58.5m
USD
|
Net Income
|
281.6m
USD
|
Free Cash Flow Analysis
Halozyme Therapeutics Inc
What is Free Cash Flow?
HALO Profitability Score
Profitability Due Diligence
Halozyme Therapeutics Inc's profitability score is 84/100. The higher the profitability score, the more profitable the company is.
Score
Halozyme Therapeutics Inc's profitability score is 84/100. The higher the profitability score, the more profitable the company is.
HALO Solvency Score
Solvency Due Diligence
Halozyme Therapeutics Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Score
Halozyme Therapeutics Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
HALO Price Targets Summary
Halozyme Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for HALO is 52.13 USD with a low forecast of 39.39 USD and a high forecast of 75.6 USD.
Ownership
HALO Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
HALO Price
Halozyme Therapeutics Inc
Average Annual Return | 44.47% |
Standard Deviation of Annual Returns | 61.83% |
Max Drawdown | -49% |
Market Capitalization | 4.9B USD |
Shares Outstanding | 127 054 000 |
Percentage of Shares Shorted | 8.4% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development and commercialization of human enzymes and drug candidates. The company is headquartered in San Diego, California and currently employs 145 full-time employees. The company went IPO on 2003-01-30. The firm licenses its technology to biopharmaceutical companies to collaboratively develop products that combine its ENHANZE drug delivery technology with the collaborators' compounds. The firm's lead enzyme, rHuPH20, is used to facilitate the delivery of injected drugs and fluids. The firm's approved product and its collaborators’ approved products and product candidates are based on rHuPH20, a patented recombinant human hyaluronidase enzyme. The firm's lead product, Hylenex recombinant, is a formulation of rHuPH20 that facilitates subcutaneous fluid administration for achieving hydration, to increase the dispersion and absorption of other injected drugs and, in subcutaneous urography, to improve resorption of radiopaque agents. The rHuPH20 can be applied as a drug delivery platform to increase dispersion and absorption of other injected drugs and fluids, potentially reducing the treatment burden.
Contact
IPO
Employees
Officers
The intrinsic value of one HALO stock under the Base Case scenario is 54.76 USD.
Compared to the current market price of 38.64 USD, Halozyme Therapeutics Inc is Undervalued by 29%.